These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 31955344)

  • 21. The medical treatment of radioiodine-refractory differentiated thyroid cancers in 2019. A TUTHYREF
    de la Fouchardiere C; Alghuzlan A; Bardet S; Borget I; Borson Chazot F; Do Cao C; Godbert Y; Leenhardt L; Zerdoud S; Leboulleux S
    Bull Cancer; 2019 Sep; 106(9):812-819. PubMed ID: 31200896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lenvatinib for the treatment of radioiodine-refractory differentiated thyroid carcinoma: a systematic review and indirect comparison with sorafenib.
    Kawalec P; Malinowska-Lipień I; Brzostek T; Kózka M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1303-1309. PubMed ID: 27734713
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment-related adverse effects with TKIs in patients with advanced or radioiodine refractory differentiated thyroid carcinoma: a systematic review and meta-analysis.
    Yu ST; Ge JN; Luo JY; Wei ZG; Sun BH; Lei ST
    Cancer Manag Res; 2019; 11():1525-1532. PubMed ID: 30863162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer.
    Kim MJ; Kim SM; Lee EK; Hwangbo Y; Lee YJ; Cho SW; Park DJ; Lee Y; Park YJ
    Endocr J; 2019 Jul; 66(7):597-604. PubMed ID: 31006722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of multikinase inhibitors/lenvatinib concomitant with radioiodine for the treatment of radioiodine refractory differentiated thyroid cancer.
    Herranz UA
    Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):47-53. PubMed ID: 36202606
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sorafenib in Japanese Patients with Locally Advanced or Metastatic Medullary Thyroid Carcinoma and Anaplastic Thyroid Carcinoma.
    Ito Y; Onoda N; Ito KI; Sugitani I; Takahashi S; Yamaguchi I; Kabu K; Tsukada K
    Thyroid; 2017 Sep; 27(9):1142-1148. PubMed ID: 28635560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of dose interruption on the efficacy of lenvatinib in a phase 3 study in patients with radioiodine-refractory differentiated thyroid cancer.
    Tahara M; Brose MS; Wirth LJ; Suzuki T; Miyagishi H; Fujino K; Dutcus CE; Gianoukakis A
    Eur J Cancer; 2019 Jan; 106():61-68. PubMed ID: 30471649
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship between toxicities and clinical benefits of newly approved tyrosine kinase inhibitors in thyroid cancer: A meta-analysis of literature.
    Ye X; Zhu Y; Cai J
    J Cancer Res Ther; 2015 Oct; 11 Suppl 2():C185-90. PubMed ID: 26506873
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and Safety of Multikinase Inhibitors for Patients With Refractory Thyroid Cancer: Systematic Review and Network Meta-Analysis.
    Jing R; Wu N; Wu Y; Zhang Q; Liang Q; Huang P; Yi S
    J Clin Endocrinol Metab; 2024 Sep; 109(10):2658-2672. PubMed ID: 38970485
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
    Brose MS; Smit JWA; Lin CC; Tori M; Bowles DW; Worden F; Shen DH; Huang SM; Tsai HJ; Alevizaki M; Peeters RP; Takahashi S; Rumyantsev P; Guan R; Babajanyan S; Ozgurdal K; Sugitani I; Pitoia F; Lamartina L
    Thyroid; 2022 Sep; 32(9):1059-1068. PubMed ID: 35950621
    [No Abstract]   [Full Text] [Related]  

  • 32. Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET.
    Marotta V; Ramundo V; Camera L; Del Prete M; Fonti R; Esposito R; Palmieri G; Salvatore M; Vitale M; Colao A; Faggiano A
    Clin Endocrinol (Oxf); 2013 May; 78(5):760-7. PubMed ID: 23009688
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas: to lenvatinib and beyond.
    Wang E; Karedan T; Perez CA
    Anticancer Drugs; 2015 Aug; 26(7):689-97. PubMed ID: 25974026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sorafenib for the treatment of thyroid cancer: an updated review.
    Krajewska J; Handkiewicz-Junak D; Jarzab B
    Expert Opin Pharmacother; 2015 Mar; 16(4):573-83. PubMed ID: 25605317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful treatment switch from lenvatinib to sorafenib in a patient with radioactive iodine-refractory differentiated thyroid cancer intolerant to lenvatinib due to severe proteinuria.
    Goto H; Kiyota N; Otsuki N; Imamura Y; Chayahara N; Suto H; Nagatani Y; Toyoda M; Mukohara T; Nibu KI; Kasahara T; Ito Y; Miya A; Hirokawa M; Miyauchi A; Minami H
    Auris Nasus Larynx; 2018 Dec; 45(6):1249-1252. PubMed ID: 29779695
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of peptide receptor radionuclide therapy in advanced radioiodine-refractory differentiated thyroid cancer and metastatic medullary thyroid cancer: a systematic review.
    Maghsoomi Z; Emami Z; Malboosbaf R; Malek M; Khamseh ME
    BMC Cancer; 2021 May; 21(1):579. PubMed ID: 34016077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sorafenib and Lenvatinib Treatment for Metastasis/Recurrence of Radioactive Iodine-refractory Differentiated Thyroid Carcinoma.
    Ito Y; Onoda N; Kudo T; Masuoka H; Higashiyama T; Kihara M; Miya A; Miyauchi A
    In Vivo; 2021; 35(2):1057-1064. PubMed ID: 33622902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigating the potential clinical benefit of Selumetinib in resensitising advanced iodine refractory differentiated thyroid cancer to radioiodine therapy (SEL-I-METRY): protocol for a multicentre UK single arm phase II trial.
    Brown SR; Hall A; Buckley HL; Flanagan L; Gonzalez de Castro D; Farnell K; Moss L; Gregory R; Newbold K; Du Y; Flux G; Wadsley J
    BMC Cancer; 2019 Jun; 19(1):582. PubMed ID: 31200667
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience.
    Cabanillas ME; Waguespack SG; Bronstein Y; Williams MD; Feng L; Hernandez M; Lopez A; Sherman SI; Busaidy NL
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2588-95. PubMed ID: 20392874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
    Ahmed M; Barbachano Y; Riddell A; Hickey J; Newbold KL; Viros A; Harrington KJ; Marais R; Nutting CM
    Eur J Endocrinol; 2011 Aug; 165(2):315-22. PubMed ID: 21566072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.